[
  {
    "biomarker_id": "A0001",
    "biomarker_component": [
      {
        "biomarker": "entry 1 increased IL6 level",
        "assessed_biomarker_entity": {
          "recommended_name": "entry 1 Interleukin-6",
          "synonyms": [
            {
              "synonym": "entry 1 Interferon-beta 2"
            },
            {
              "synonym": "entry 1 IL6"
            },
            {
              "synonym": "entry 1 IFNB2"
            }
          ]
        },
        "assessed_biomarker_entity_id": "entry 1 UPKB:p05231",
        "assessed_entity_type": "entry 1 protein",
        "specimen": [
          {
            "name": "entry 1 blood",
            "id": "entry 1 UBERON:0000178",
            "name_space": "entry 1 UBERON",
            "url": "http://purl.obolibrary.org/obo/UBERON_0000178",
            "loinc_code": "entry 1 26881-3"
          }
        ],
        "evidence_source": [
          {
            "id": "entry 1 10914713",
            "database": "entry 1 PubMed",
            "url": "https://pubmed.ncbi.nlm.nih.gov/10914713/",
            "evidence_list": [
              {
                "evidence": "entry 1 In multivariate analysis, however, the only two significant prognostic factors were EOD and IL-6. These results indicate that the serum IL-6 level is a significant prognostic factor for prostate cancer as well as EOD."
              }
            ],
            "tags": [
              {
                "tag": "biomarker"
              },
              {
                "tag": "specimen:UBERON:0000178"
              }
            ]
          }
        ]
      }
    ],
    "best_biomarker_role": [
      {
        "role": "prognostic"
      }
    ],
    "condition": {
      "id": "entry 1 DOID:10283",
      "recommended_name": {
        "id": "entry 1 DOID:10283",
        "name": "entry 1 prostate cancer",
        "description": "entry 1 A male reproductive organ cancer that is located_in the prostate.",
        "resource": "entry 1 Disease Ontology",
        "url": "http://disease-ontology.org/term/DOID:10283"
      },
      "synonyms": [
        {
          "id": "entry 1 DOID:10283",
          "name": "entry 1 NGP - new growth of prostate",
          "resource": "entry 1 Disease Ontology",
          "url": "http://disease-ontology.org/term/DOID:10283"
        },
        {
          "id": "entry 1 DOID:10283",
          "name": "entry 1 hereditary prostate cancer",
          "resource": "entry 1 Disease Ontology",
          "url": "http://disease-ontology.org/term/DOID:10283"
        }
      ]
    },
    "evidence_source": [
      {
        "id": "entry 1 10914713",
        "database": "entry 1 PubMed",
        "url": "https://pubmed.ncbi.nlm.nih.gov/10914713/",
        "evidence_list": [
          {
            "evidence": "entry 1 In multivariate analysis, however, the only two significant prognostic factors were EOD and IL-6. These results indicate that the serum IL-6 level is a significant prognostic factor for prostate cancer as well as EOD."
          }
        ],
        "tags": [
          {
            "tag": "biomarker:0"
          },
          {
            "tag": "specimen:UBERON:0000178:0"
          }
        ]
      }
    ],
    "citation": [
      {
        "citation_title": "Serum interleukin 6 as a prognostic factor in patients with prostate cancer",
        "journal": "Clin Cancer Res",
        "authors": "J Nakashima, M Tachibana, Y Horiguchi, M Oya, T Ohigashi, H Asakura, M Murai",
        "date": "July 6, 2000",
        "reference": [
          {
            "id": "10914713",
            "type": "PubMed",
            "url": "https://pubmed.ncbi.nlm.nih.gov/10914713/"
          }
        ],
        "evidence_source": [
          {
            "id": "10914713",
            "database": "PubMed",
            "url": "https://pubmed.ncbi.nlm.nih.gov/10914713/"
          }
        ]
      }
    ]
  },
  {
    "biomarker_id": "A0002",
    "biomarker_component": [
      {
        "biomarker": "entry 2 increased IL6 level",
        "assessed_biomarker_entity": {
          "recommended_name": "entry 2 Interleukin-6",
          "synonyms": [
            {
              "synonym": "entry 2 Interferon-beta 2"
            },
            {
              "synonym": "entry 2 IL6"
            },
            {
              "synonym": "entry 2 IFNB2"
            }
          ]
        },
        "assessed_biomarker_entity_id": "entry 2 UPKB:p05231",
        "assessed_entity_type": "entry 2 protein",
        "specimen": [
          {
            "name": "entry 2 blood",
            "id": "entry 2 UBERON:0000178",
            "name_space": "entry 2 UBERON",
            "url": "http://purl.obolibrary.org/obo/UBERON_0000178",
            "loinc_code": "entry 2 26881-3"
          }
        ],
        "evidence_source": [
          {
            "id": "entry 2 10914713",
            "database": "entry 2 PubMed",
            "url": "https://pubmed.ncbi.nlm.nih.gov/10914713/",
            "evidence_list": [
              {
                "evidence": "entry 2 In multivariate analysis, however, the only two significant prognostic factors were EOD and IL-6. These results indicate that the serum IL-6 level is a significant prognostic factor for prostate cancer as well as EOD."
              }
            ],
            "tags": [
              {
                "tag": "biomarker"
              },
              {
                "tag": "specimen:UBERON:0000178"
              }
            ]
          }
        ]
      }
    ],
    "best_biomarker_role": [
      {
        "role": "predictive"
      }
    ],
    "condition": {
      "id": "entry 2 DOID:10283",
      "recommended_name": {
        "id": "entry 2 DOID:10283",
        "name": "entry 2 prostate cancer",
        "description": "entry 2 A male reproductive organ cancer that is located_in the prostate.",
        "resource": "entry 2 Disease Ontology",
        "url": "http://disease-ontology.org/term/DOID:10283"
      },
      "synonyms": [
        {
          "id": "entry 2 DOID:10283",
          "name": "entry 2 NGP - new growth of prostate",
          "resource": "entry 2 Disease Ontology",
          "url": "http://disease-ontology.org/term/DOID:10283"
        },
        {
          "id": "entry 2 DOID:10283",
          "name": "entry 2 hereditary prostate cancer",
          "resource": "entry 2 Disease Ontology",
          "url": "http://disease-ontology.org/term/DOID:10283"
        }
      ]
    },
    "evidence_source": [
      {
        "id": "entry 2 10914713",
        "database": "entry 2 PubMed",
        "url": "https://pubmed.ncbi.nlm.nih.gov/10914713/",
        "evidence_list": [
          {
            "evidence": "entry 2 In multivariate analysis, however, the only two significant prognostic factors were EOD and IL-6. These results indicate that the serum IL-6 level is a significant prognostic factor for prostate cancer as well as EOD."
          }
        ],
        "tags": [
          {
            "tag": "biomarker:0"
          },
          {
            "tag": "specimen:UBERON:0000178:0"
          }
        ]
      }
    ],
    "citation": [
      {
        "citation_title": "Serum interleukin 6 as a prognostic factor in patients with prostate cancer",
        "journal": "Clin Cancer Res",
        "authors": "J Nakashima, M Tachibana, Y Horiguchi, M Oya, T Ohigashi, H Asakura, M Murai",
        "date": "July 6, 2000",
        "reference": [
          {
            "id": "10914713",
            "type": "PubMed",
            "url": "https://pubmed.ncbi.nlm.nih.gov/10914713/"
          }
        ],
        "evidence_source": [
          {
            "id": "10914713",
            "database": "PubMed",
            "url": "https://pubmed.ncbi.nlm.nih.gov/10914713/"
          }
        ]
      }
    ]
  }
]
